Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild and Moderate Renal Impairment and Normal Renal Function After a Single Oral Administration

Next Previous
Trial Profile

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild and Moderate Renal Impairment and Normal Renal Function After a Single Oral Administration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mufemilast (Primary)
  • Indications Ankylosing spondylitis; Atopic dermatitis; Behcet's syndrome; Plaque psoriasis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Ganzhou Hemay Pharmaceutical

Most Recent Events

  • 04 Dec 2025 Status changed from recruiting to completed.
  • 19 Mar 2025 Planned End Date changed from 1 Dec 2024 to 31 Dec 2025.
  • 19 Mar 2025 Planned primary completion date changed from 1 Dec 2024 to 30 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top